Lv4
402 积分 2022-05-11 加入
First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis
23天前
已完结
Rezvilutamide in metastatic hormone-sensitive prostate cancer: interpreting CHART trial evidence and clinical applicability in the European Association of Urology guidelines
23天前
已关闭
Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer
23天前
已完结
Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer
23天前
已完结
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
1个月前
已完结
Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial
1个月前
已完结
Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial
1个月前
已完结
Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design
1个月前
已完结
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
1个月前
已完结
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design
1个月前
已完结
皖公网安备34019202002308
